A pharmacokinetic bridging study of NKPL66 (CaPre)

Trial Profile

A pharmacokinetic bridging study of NKPL66 (CaPre)

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2017

At a glance

  • Drugs NKPL 66 (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Pharmacokinetics
  • Sponsors Acasti Pharma
  • Most Recent Events

    • 07 Jun 2017 According to an Acasti Pharma media release, results from this study were presented at the National Lipid Association Scientific Sessions.
    • 12 Apr 2017 Results will be presented at the National Lipid Association Scientific Sessions 2017, according to an Acasti Pharma media release.
    • 12 Jan 2017 According to an Acasti Pharma media release, the full report of this study has been submitted to the FDA. Company plans to discuss the results of this study and gain guidance on planned Phase 3 clinical study protocol in patients with severe hypertriglyceridemia (see profile 272010) with the FDA in a meeting scheduled in the first quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top